S
Shenzhen Myway Medical Technology
Innovative multimodal therapeutic devices for cardiac electrophysiology, renal denervation, and tumor ablation
About Shenzhen Myway Medical Technology
PulseCare, founded in July 2021 and headquartered in Shenzhen, China, specializes in developing advanced multimodal therapeutic devices. Utilizing cutting-edge multimodal energy platform technology, PulseCare has introduced a range of products including nsPFA cardiac electrophysiology ablation, ultrasound renal denervation (RDN), and multimodal tumor ablation systems. These products are specifically designed to meet the diverse clinical needs for various medical conditions. PulseCare primarily serves healthcare providers, including hospitals and specialized clinics, focusing on minimally invasive and non-invasive treatment options. The company operates in the medical device market, which is characterized by rapid technological advancements and stringent regulatory requirements. PulseCare's business model revolves around the development, manufacturing, and distribution of its innovative therapeutic devices. Revenue is generated through the sale of these devices to healthcare institutions and through partnerships with medical professionals. By continually advancing its technology and expanding its product portfolio, PulseCare aims to become a leading international player in the field of multimodal minimally invasive and non-invasive therapeutic devices.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- 3
- Dealroom signal
- 21.0/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Oncology, Surgery, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Aug 2024 | $14M | $55M | Tasly Pharmaceutical Group · Tianfeng Capital · Delian Capital | ↗ |
Growth signals
Latest recorded traffic for Shenzhen Myway Medical Technology is 300 monthly website visits, down 53.8% over the last three months.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shenzhen Myway Medical Technology in the Ningbo ecosystem
The Shenzhen Myway Medical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Tasly Pharmaceutical Group- TCTianfeng Capital
Delian Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shenzhen Myway Medical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shenzhen Myway Medical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






